Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 6/20 | 0.45 |
| ▸ | PSMB9 | P28065 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916371 | 0.96 | ACHE (0.44) | ACHEPSMB8PSMB9JAK2JAK1 | |
| SCHEMBL22031498 | 0.92 | ACHE (0.39) | ACHEPSMB8PSMB9HCRTR1HCRTR2 | |
| SCHEMBL24723288 | 0.84 | ALOX15 (0.41) | ACHECLK2BMPR1AACVRL1ACVR1 | |
| SCHEMBL15330753 | 0.84 | CHRNB2 (0.48) | JAK2CHRNB2CHRNA4ACVRL1ACVR1 | |
| SCHEMBL16101793 | 0.84 | LRRK2 (0.39) | ACHEPSMB8PSMB9JAK2JAK1 | |
| SCHEMBL16101792 | 0.82 | LRRK2 (0.35) | ACHEPSMB8PSMB9JAK2JAK1 | |
| SCHEMBL24723107 | 0.82 | MELK (0.36) | ACHEPSMB8PSMB9 | |
| SCHEMBL18706528 | 0.80 | PIM1 (0.39) | ACHEPSMB8PSMB9JAK2HCRTR1 | |
| SCHEMBL23763044 | 0.78 | LRRK2 (0.41) | JAK2JAK1JAK3HCRTR1HCRTR2 | |
| SCHEMBL22585673 | 0.78 | LRRK2 (0.40) | ACHEPSMB8PSMB9LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| US-8569281-B2 | Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-29 | — | — | US | disclosed |
| EP-2619201-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20120295883-A1 | COMPOUNDS | GENENTECH, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012038743-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | ACHE 1360/4885PSMB8 3586/4885PSMB9 4006/4885 |
| US-20120295883-A1 | COMPOUNDS | ABCC5, PRNP, PC | ACHE 58/4885PSMB8 4696/4885PSMB9 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.